Pasar al contenido principal


Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Conexión rápida

Productos Genéricos

Finished Dosage Forms - Product List:

Download Brochure

Dr. Reddy’s Laboratories is a leading API supplier, with a presence in over 80 countries and a portfolio of 200+ ANDA filings and approved dossiers. Our offering goes beyond APIs and our global customers have access to high-quality dossiers and finished dosage forms.

Generics Product List
Therapy Area : Oncologia
Product Name Oral Inj Strength Dossier Status Connect
Bendamustine RTU Filed
Bortezomib Filed
Cabazitaxel Filed
Carfilzomib Filed
Decitabine Filed
Eribulin En desarrollo
Fulvestrant Filed
Fosaprepitant Filed
Liposomal Doxorubicin Filed
Palonosetron Filed
Pemetrexed Filed
Plerixafor Filed
Zoledronic Acid Filed
Abiraterone Filed
Capecitabine Filed
Dasatinib Filed
Enzalutamide En desarrollo
Everolimus En desarrollo
Lenalidomide Filed
Lenvatinib En desarrollo
Nilotinib En desarrollo
Palbociclib Filed
Pomalidomide Filed
Fingolimod Filed
Abiraterone En desarrollo
Imatinib Mesylate Filed
Carmustine Filed
Venetoclax Filed
Sorafenib Filed
Midostaurin Filed
Sunitinib Malate Filed
Nano Paclitaxel 100mg En desarrollo
Axitinib En desarrollo
Cabozantinib En desarrollo
Sunitinib Filed
Tofacitinib XR Tofacitinib XR En desarrollo
Pazopanib En desarrollo
Dimethyl Fumarate En desarrollo
Nintedanib En desarrollo
Azacitidina Filed
Bendamustina Filed
Therapy Area : Sistema nervioso central
Product Name Oral Inj Strength Dossier Status Connect
Glatiramer Filed
Sugammadex Filed
Pregabalin Filed
Therapy Area : Cardiovascular
Product Name Oral Inj Strength Dossier Status Connect
Fondaparinux Filed
Treprostinil Filed
Apixaban Filed
Dabigatran Filed
Rivaroxaban Filed
Sacubitril/ Valsartan Filed
Ticagrelor Filed
Icosapent Ethy Filed
Therapy Area : Anti-diabético
Product Name Oral Inj Strength Dossier Status Connect
Liraglutide En desarrollo
Canagliflozin + Metformin Filed
Linagliptin Filed
Linagliptin + Metformin Filed
Semaglutide En desarrollo
Therapy Area : Gastro-Intestinal
Product Name Oral Inj Strength Dossier Status Connect
Esomeprazole Filed
Esomeprazole MG + Naproxen Na Filed
Lansoprazole ODT Filed
Therapy Area : Otras
Product Name Oral Inj Strength Dossier Status Connect
Daptomycin Filed
Icatibant Filed
Iron Sucrose Filed
Sevelamer Carbonate Filed
Valganciclovir Filed
Isotretinoin Filed
Varenicline Filed
Ferric Carboxy Maltose En desarrollo
Teriparatide En desarrollo
Rifaximine En desarrollo
Amphotericin B En desarrollo
Mesalamine En desarrollo
阿普斯特 Filed
Therapy Area : Oncology / Acromegaly
Product Name Oral Inj Strength Dossier Status Connect
Octerotide En desarrollo
Lanreotide En desarrollo
Therapy Area : Anti-Obesity
Product Name Oral Inj Strength Dossier Status Connect
Liraglutide En desarrollo
Therapy Area : Immuno Suppressant
Product Name Oral Inj Strength Dossier Status Connect
Sirolimus Filed
Tacrolimus Filed
Therapy Area Product Name Dosage Form EU Approval Status US Approval Status
Oncology Doxorubicin Hydrochloride Liposome Injection, 20 mg/10 ml (2 mg/ml) and 50 mg/25 ml (2 mg/ml) Single-dose Vials Injection Under review Approved
Oncology Imatinib Mesylate Tablets 100/400 mg Tablets NA Approved
Oncology Imatinib Mesylate Capsules 50/100/400 mg Capsules Approved NA
Oncology Docetaxel Injection Concentrate and 80 mg/4 ml Injection Approved Approved
Oncology Bendamustine HCl Concentrate for Solution for Infusion 180 mg_4 ml Infusion Approved NA
Oncology Bendamustine Hydrochloride Injection 25 mg/Vial and 100 mg/Vial Injection NA Tentative Approved
Oncology Capecitabine Tablets 500 mg Tablets Approved Approved
Oncology Capecitabine Tablets 150 mg Tablets NA Approved
Oncology Fulvestrant Injection 250 mg/5 ml (50 mg/ml) Injection Approved Approved
Oncology Dasatinib 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, 140 mg Film tablet Tablets Under review Tentative Approved

Meet with our product experts in one-on-one virtual sessions

Our experts will answer your questions, provide advice, and help you understand our product better

Set Up a Meeting

X

Let’s talk API sourcing live at

Tackle sourcing bottlenecks and compliance hurdles

Hall E1 Booth H28 24-26 June 2025, Shanghai

Book a Meeting